Bristol Myers to merge scientific, clinical teams under new R&D structure

By Reuters News

- Bristol Myers Squibb BMY.N said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.

Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.

  • "Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," said CEO Christopher Boerner

  • Analysts are closely watching Bristol's drug development pipeline for clues on growth

  • "Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution," Boerner said

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.